20 (AIDX) Cash & Equivalents (2024 - 2026)

20's (AIDX) quarterly Cash & Equivalents came in at $4.2 million in Q1 2026, up 311.22% on a QoQ basis from $1.0 million in Q4 2025.

20 (AIDX) Cash & Equivalents (2024 - 2026) Analysis & Trends

20 (AIDX) has 3 years of Cash & Equivalents data on file, last reported at $4.2 million in Q1 2026.

Quarterly Cash & Equivalents changed N/A year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (changed N/A YoY) and the FY2025 annual result came in at $1.0 million, down 42.49% from the prior year.
Cash & Equivalents grew to $4.2 million in Q1 2026, from $1.0 million in the prior quarter.
In the past five years, Cash & Equivalents ranged from a high of $4.2 million in Q1 2026 to a low of $1.0 million in Q4 2025.
A 3-year average of $2.3 million and a median of $1.8 million in 2024 frame the typical range for Cash & Equivalents.
The widest YoY moves for Cash & Equivalents: up 42.49% in 2025, down 42.49% in 2025.
Tracing AIDX's Cash & Equivalents over 3 years: stood at $1.8 million in 2024, then slumped by 42.49% to $1.0 million in 2025, then jumped by 311.22% to $4.2 million in 2026.
The last three Cash & Equivalents figures came in at $4.2 million (Q1 2026), $1.0 million (Q4 2025), and $1.8 million (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash & Equiv. (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	5.10 Bn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	3.39 Bn
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	1.95 Bn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	539.00 Mn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	2.91 Bn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	1.11 Bn
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	2.11 Bn
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	3.25 Bn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	482.30 Mn
10	20	5.55 Mn	1.00 Mn	304,727.00	4.55 Mn

Download Data